Centralization of genomics-bioinformatics will provide the SPORE investigators with access to the state-of- the-art genomic capability and bioinformatics expertise, by leveraging existing institutional infrastructure such as Harvard/Partners Center for Genomics and Genetics and the Belfer Cancer Genomics Center. An important benefit derived from centralization comes from improved data storage and sharing, allowing for better integration of ideas and information across the various projects within the SPORE. Moreover, given the pace of discovery in areas of genomics and bioinformatics, it is difficult to predict where the field will stand even one year in advance. This invariant feature of change provides justification for a core with strong technical implementation capability and intellectual leadership throughout the granting period, so that the best technology will be brought to bear on the biological questions of the SPORE. This Core will provide several levels of support to the SPORE. First, it will offer bioinformatics consultation, in collaboration with Biostatistics, to assist all projects in the design and preliminary analyses of genomic studies, including copy number and expression profiling as well as gene re-sequencing. In this process, the Core will serve the central coordinating role in data receipt/storage for genomic assays in all projects, so that integrated analyses can be performed more easily. Second, the Core will leverage existing institutional infrastructure for established capabilities such as expression profiling and candidate gene re-sequencing. In addition, the Core will bring to the SPORE unique capability in high-resolution copy number profiling by array-CGH. Third, the Core will provide custom-designed tools and bioinformatics expertise for mining copy number data with integrated expression analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-02
Application #
7662344
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$142,196
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Strickler, John H; Loree, Jonathan M; Ahronian, Leanne G et al. (2018) Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov 8:164-173
Khalaf, Natalia; Yuan, Chen; Hamada, Tsuyoshi et al. (2018) Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology 154:1380-1390.e5
Hamada, Tsuyoshi; Liu, Li; Nowak, Jonathan A et al. (2018) Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer 103:98-107
Qian, Zhi Rong; Rubinson, Douglas A; Nowak, Jonathan A et al. (2018) Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol 4:e173420
Nevo, Daniel; Nishihara, Reiko; Ogino, Shuji et al. (2018) The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure. Lifetime Data Anal 24:425-442
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Aguirre, Andrew J; Nowak, Jonathan A; Camarda, Nicholas D et al. (2018) Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8:1096-1111
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451

Showing the most recent 10 out of 590 publications